Metastatic prostate cancer: Abiraterone tied to worse cardiovascular outcomes

Key clinical point: Compared with enzalutamide, abiraterone was associated with a 31% higher risk for myocardial infarction or stroke in patients with metastatic prostate cancer.

Major finding: Abiraterone vs. enzalutamide was associated with an increased risk for myocardial infarction or stroke (hazard ratio [HR], 1.31; P = .01). A higher risk for stroke was observed in patients who received abiraterone vs enzalutamide (HR, 1.52; P = .008). No difference was seen in the risk for myocardial infarction between the 2 treatments (P = .92).

Study details: A retrospective study of 6,294 patients with metastatic prostate cancer who received androgen deprivation therapy with either abiraterone or enzalutamide.

,

Disclosures: No funding source was identified for this study. The authors received research funding, advisory/speaker fees, and/or honoraria from various sources.

Source: Kulkarni AA et al. ESMO Open. 2021 Sep 9. doi: 10.1016/j.esmoop.2021.100261.